Am. J. Trop. Med. Hyg., 83(5), 2010, pp. 1059–1065
doi:10.4269/ajtmh.2010.10-0263
Copyright © 2010 by The American Society of Tropical Medicine and Hygiene
A Genotypic Approach for Detection, Identification, and Characterization of Drug Resistance
in Mycobacterium ulcerans in Clinical Samples and Isolates from Ghana
Marcus Beissner,* Nana-Yaa Awua-Boateng, William Thompson, Willemien A. Nienhuis, Erasmus Klutse, Pius Agbenorku,
Joerg Nitschke, Karl-Heinz Herbinger, Vera Siegmund, Erna Fleischmann, Ohene Adjei, Bernhard Fleischer,
Tjip S. van der Werf, Thomas Loscher, and Gisela Bretzel
Department of Infectious Diseases and Tropical Medicine (DITM), University Hospital, Ludwig-Maximilians University of Munich, Munich,
Germany; Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), Kwame Nkrumah University of Science and Technology
(KNUST), Kumasi, Ghana; Agogo Presbyterian Hospital, Agogo, Ghana; University Medical Centre Groningen (UMCG), University of Groningen,
Groningen, The Netherlands; Dunkwa Governmental Hospital, Dunkwa-on-Offin, Dunkwa, Ghana; Reconstructive Plastic Surgery and Burns Unit,
Department of Surgery, Komfo Anokye Teaching Hospital, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Bernhard
Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany
Abstract. Standardized antimycobacterial therapy is considered the treatment of choice for Buruli ulcer disease.
To assess the prevalence of drug resistance among clinical Mycobacterium ulcerans isolates in Ghana, we conducted a
sequence-based approach to detect mutations associated with drug resistance. We subjected clinical samples to direct
DNA sequencing of rpoB and rpsL genes and compared culture and whole-genome extracts regarding the efficiency of
sequence analysis; 99.1% (rpoB) and 100% (rpsL) of the patients harbored M. ulcerans wild type. In one isolate (0.9%), a
point mutation of the rpoB gene at codon Ser522 leading to an amino acid change was detected. Culture extracts yielded
a significantly higher sequencing efficiency than whole-genome extracts. Our data suggest a low level of drug resistance
in Ghana. However, mutations associated with drug resistance do occur and require monitoring. Improved techniques are
necessary to enhance the efficiency of sequence analysis of whole-genome extracts.
INTRODUCTION
resistance surveillance for leprosy and implemented a genotypic drug-resistance surveillance system in 2009. So far, high
concordance between conventional drug-susceptibility testing
(mouse footpad technique) and DNA sequencing methods
has been observed. In a large-scale study on sequence-based
detection of drug resistance in human leprosy, rifampicinresistant M. leprae strains were detected among 2% of new
cases and 8% of relapses in Southeast Asia.9–11
The majority of M. tuberculosis strains expressing phenotypic resistance to rifampicin shows mutations within the
highly conserved 81-bp RMP resistance-determining region
(RRDR) of the rpoB gene comprising codons 507–533, with
codons Ser531 and His526 being involved most frequently.12 For
M. leprae, rpoB gene mutations leading to phenotypic rifampicin resistance were likewise detected within the RRDR
comprising codons 401–427 (equivalent to codons 507–533
in M. tuberculosis), predominantly affecting codon Ser425
(equivalent to Ser531 in M. tuberculosis).13 Resistance of
M. tuberculosis to SM was most frequently associated with a
single mutation in codon 43 of the rpsL gene and less commonly with mutations of the rrs gene.14,15
To date, clinical M. ulcerans strains resistant to RMP or
SM have not yet been reported. However, mutations of the
rpoB gene in codons Ser416 and His420 (Ser522 and His526 in
M. tuberculosis numbering, respectively) of three M. ulcerans
strains causing RMP-resistant phenotypes have been detected
after RMP monotherapy of experimentally infected mice.16
With respect to the irregular use of antimycobacterial drugs
before introduction of standardized antimycobacterial treatment, we conducted a pilot study in Ghana to evaluate the
potential use of molecular tools, specifically gene sequencing,
to obtain baseline data on the prevalence of mutations possibly associated with resistance of M. ulcerans to RMP and SM.
Buruli ulcer disease (BUD), caused by Mycobacterium
ulcerans, is the third most common mycobacterial infection
in humans after tuberculosis and leprosy, and it has been
reported from more than 30 countries worldwide, with dominant endemic foci in West Africa. BUD involves the skin
and the subcutaneous adipose tissue. The disease starts as a
painless nodule, papule, plaque, or edema and evolves into
a painless ulcer with characteristically undermined edges. If
left untreated, severe disability may occur. Previously, BUD
was treated by wide surgical excision, and the World Health
Organization (WHO) recommended antimycobacterial
treatment of 56 days with streptomycin (SM) and rifampicin
(RMP), if necessary, followed by surgical excision in 2004.1,2
Most West African countries implemented the standardized antibiotic therapy in 2006. However, non-standardized
regimens of RMP and/or SM were also used as concomitant
treatment before or after surgical interventions before 2006.3–5
Although effective and in many aspects advantageous over
surgery, introduction of antimycobacterial treatment poses
new challenges for the management of BUD.1
As is well-known from tuberculosis and leprosy, antimycobacterial treatment is prone to the development of drug
resistance. Risk factors hereby encompass a lack of patients’
compliance as well as irregular and inadequate treatment regimens in terms of duration, dosage, and drug combination. The
WHO estimates the current global level of drug resistance of
M. tuberculosis complex (MTBC) to RMP and SM, as determined by the proportion method, to be 6.3% and 12.6%,
respectively.6 Genotypic drug-resistance testing constitutes a
reliable and expedient alternative to predict phenotypic drug
resistance of M. tuberculosis to RMP and SM.7,8 In 2007, WHO
also emphasized the importance of systematic global drug
MATERIALS AND METHODS
* Address correspondence to Marcus Beissner, Department of Infectious
Diseases and Tropical Medicine (DITM), University Hospital, LudwigMaximilians University of Munich, Leopoldstrasse 5, 80802 Munich,
Germany. E-mail: marcus.beissner@lrz.uni-muenchen.de
Ethics statement. The study was approved by the
Committee of Human Research Publication and Ethics,
1059
1060
BEISSNER AND OTHERS
School of Medical Sciences, Kwame Nkrumah University of
Science and Technology, Kumasi, Ghana (CHRPE/07/01/05).
For all patients who were enrolled in a drug trial, written
informed consent was obtained from the study participants
and/or their legal representatives if aged under 18 years. For
patients who underwent routine surgical treatment (with or
without concomitant drug therapy), written consent or in the
case of the participants who were illiterate, verbal consent,
according to the requirements of the ethics committee, for
all treatment-related procedures including the collection of
diagnostic specimens was obtained in the treatment centers
and documented in the medical records of the respective
patients.
Patients. One hundred sixty-two laboratory-confirmed
BUD patients with ulcerative (N = 99) and non-ulcerative (N =
63) lesions seeking treatment in five treatment centers in Ghana
(Agogo Presbyterian Hospital, N = 116; Nkawie Government
Hospital, N = 30; Dunkwa Government Hospital, N = 12;
Global Evangelican Mission Hospital, Apromase-Ashanti, N =
3; Goaso Hospital, N = 1) were enrolled in the study.
Between 2004 and 2007, 80 patients (49.4%) were treated by
surgical excision with or without concomitant antimycobacterial treatment. At the time of collection of clinical samples, 29
of those patients (36.3%) had not received any antimycobac-
terial drugs (ST). Thirty-two patients (40.0%) had received
either a combination of RMP and SM (N = 30) or RMP alone
(N = 2; ST+). Fourteen patients were treated for ≤ 7 days
(short-term; ST+S), and two of those patients received RMP
only. Twelve patients received 8–28 days of drug treatment
(intermediate; ST+IN), and six were treated for 29–42 days
(long term; ST+L). Nineteen patients (23.8%) had received
antimycobacterial treatment; however, detailed information
on the drugs applied and duration of treatment was not available (ST-NK). The mean duration of treatment before surgical excision and collection of clinical samples was 13.1 days
(Table 1).
Between 2005 and 2007, according to the clinical records,
82 patients (50.6%) were treated with antimycobacterial drugs
alone (DT). Of these, 44 patients were enrolled in a randomized controlled drug trial.17 By the time of collection of clinical
samples, 81 (98.8%) of these patients had not received antibiotics; one recurrent case, however, had received a full course
of RMP and SM before the trial (Table 1).
Clinical samples for follow-up analysis were available from
seven patients (antimycobacterial treatment only, N = 6; antibiotics plus surgery, N = 1). At the time of collection of followup samples, five patients had received full-term treatment with
RMP and SM for 56 days, and two patients were treated with
Table 1
Sequencing results of 162 BUD patients in different treatment groups
Results per patient||
rpoB gene results**
Treatment group*
DT
ST
Patients†
Culture extracts‡
Swab extracts§
50
37
MUT
NR
40
82
56 (68.3)
0
26 (31.7)
82
53 (64.6)
0
29 (35.4)
14
22
29
19 (65.5)
0
10 (34.5)
7
3 (42.9)
0
4 (57.1)
9
8
14
7 (50.0)
0
7 (50.0)
13
5 (38.5)
0
8 (61.5)
4
10
12
4 (33.3)
0
8 (66.7)
11
4 (36.4)
0
7 (63.6)
6
5 (83.3)
0
1 (16.7)
6
5 (83.3)
0
1 (16.7)
1 (5.3)
1 (5.3)
0
2 (33.3)
6
2
5
19
16
Total|| ||
WT
12
5
ST+NK
rpsL gene results††
NR¶¶
14
1
ST+L
MUT§§
29
1
ST+IN
WT‡‡
82
14
ST+S
Tissue extracts¶
162
87
2
68
Definite results
No results
3
88
19
17 (89.5)
162 (100%)
109 (67.3%)
108 (99.1%)
6
4 (66.7)
125 (100%)
74 (59.2%)
74 (59.2%) 0
1 (0.9%)
53 (32.7%)
51 (40.8%)
Table 1 provides sequencing results of M. ulcerans isolates from 162 PCR-confirmed BUD patients. Two hundred forty-three DNA extracts were analyzed from these patients, and one final
consensus result per patient is shown. From seven follow-up patients, sequencing results of isolates from visit one are listed only.
* Patients were divided into different treatment groups as follows. DT = drug treatment [patients received a full course of rifampicin (RMP) and streptomycin (SM) for 56 days after specimen
collection; one recurrent case, however, had received a full term of antimycobacterial treatment at the time of specimen collection]; ST = surgical treatment (patients were treated by surgical excision only); ST+S = surgical treatment plus short-term antimycobacterial treatment before specimen collection with RMP and SM for ≤ 7 days (two patients received RMP only); ST+IN = surgical
treatment plus intermediate-term antimycobacterial treatment before specimen collection with RMP and SM for 8–28 days; ST+L = surgical treatment plus long-term antimycobacterial treatment
before specimen collection with RMP and SM for > 28 days; ST+NK = patients were surgically treated and had received antibiotics before specimen collection, but exact treatment data was missing in clinical records.
† Number of patients per treatment group.
‡ Number of analyzed culture extracts from swab and/or tissue specimens.
§ Number of sequenced whole-genome extracts from swab specimens.
¶ Number of sequenced whole-genome extracts from tissue specimens.
|| Final sequencing result per patient. Percentages are given in brackets.
** RpoB is the gene for RNA polymerase β subunit (partial sequence = 342 bp).
†† RpsL is the gene for ribosomal protein S12 (complete sequence = 375 bp).
‡‡ WT = wild type. The analyzed sequence corresponds 100% to the WT nucleotides of M. ulcerans strain Agy99 (accession number CP000325).
§§ MUT = mutation. One isolate showed a point MUT at Ser522 of the rpoB gene. Species identification by sequence analysis of genes for 16S rRNA, rpsL, hsp65, and the ITS allowed the distinct
allocation to M. ulcerans strain Agy99 (accession number CP000325) by 100% nucleotide concordance.
¶¶ NR = no result. Sequences were non-analyzable because of mixed sequences, deviation > 3% from M. ulcerans wild type, or inability to amplify.
|| || From 24 patients, a swab and a tissue extract were sequenced; additionally, 12 culture extracts were analyzed from these patients. For 45 patients, a swab or tissue extract was available with a
corresponding culture extract inoculated from the respective clinical specimen.
1061
GENOTYPIC DRUG RESISTANCE TESTING IN M. ULCERANS
RMP and SM for 21 days. Analysis of these specimens was
done separately and is not provided in the attached tables.
Clinical samples and laboratory confirmation. Clinical samples for laboratory confirmation were collected according to
standardized procedures. Hereby, diagnostic swabs and tissue
specimens from surgical patients were collected at the time of
surgery, and diagnostic swabs and punch biopsies were collected
from patients receiving antimycobacterial treatment before
onset of treatment. As described elsewhere, the clinical samples were subjected to a dry-reagent based IS2404 polymerase
chain reaction (DRB-PCR) and culture on LoewensteinJensen media at the Kumasi Center for Collaborative
Research in Tropical Medicine, Kumasi, Ghana (KCCR)
according to standardized procedures, including external quality assurance by standard IS2404 PCR. Mycobacterial cultures
were subjected to a confirmatory IS2404 PCR.3,5,18–21
Samples subjected to sequence analysis. Suspensions of
IS2404 PCR confirmed M. ulcerans cultures (N = 87) dissolved
in 700 µL Cell Lysis Solution (Qiagen, Hilden, Germany)
followed by inactivation at 80°C for 20 minutes, and IS2404
PCR-positive whole-genome extracts (total of 156 genome
extracts) derived from swab (N = 68) and tissue samples (N
= 88) were subjected to sequence analysis of rpoB and rpsL
genes at the Department of Infectious Diseases and Tropical
Medicine, University of Munich (DITM). Samples were stored
at −20°C before shipment and on arrival at DITM, and shipment
(courier service) was conducted at ambient temperature.
Briefly, DNA was prepared using the Puregene DNA isolation
kit (Gentra Systems) as described elsewhere (Table 1).19
Amplification of rpoB and rpsL genes. A partial sequence
of the mycobacterial rpoB gene (342 bp) encompassing the
RRDR was amplified by Mycobacterium genus-specific
primers as described by Kim and others.22
A set of Mycobacterium genus-specific primers (rpsL-F:
5′-AAC AGC GAG AAC GAA AGC C- 3′; rpsL-R: 5′-TCA
CCA GTT GCG TGA CCA G-3′) was used to amplify a
sequence, including the entire rpsL gene (375 bp). The thermal-cycling protocol consisted of initial denaturation at 95°C
(7 minutes) followed by 37 repeats [95°C (20 seconds), 52°C
(25 seconds), and 72°C (45 seconds)] and a final extension at
72°C (5 minutes). Because of the very low frequency of rrs gene
mutation reported from phenotypic SM-resistant isolates of
the MTBC, we did not analyze this region in M. ulcerans.14,15
Gel extraction of PCR products. Amplicons were
electrophoresed in a 1.2% agarose gel prepared with TrisAcetate EDTA (TAE) buffer light (Roth, Karlsruhe, Germany).
Positive bands where cut out with a single sterile scalpel for
each amplicon. Purification was carried out using the Millipore
Ultrafree DA kit (Roth).
DNA sequencing. Cycle sequencing was performed according to the manufacturer’s protocol on an ABI3730 automatic
sequencer (Applied Biosystems, Darmstadt, Germany) at
Helmholtz Research Center, Neuherberg, Germany. For each
gene, a forward and a reverse sequence were generated.
Species identification. In case deviant nucleotide sequences
from M. ulcerans wild type (Agy99, complete genome; accession
number CP000325) were detected, verification of the species
M. ulcerans or identification of a contamination by another
species was attempted by sequence analysis of the following
genes using Mycobacterium genus-specific primers: 16S rRNA
gene (924 bp), 65 kDa heat shock protein (HSP) gene (644
bp), and 16S-23S rRNA internal transcribed spacer gene (ITS;
220 bp) in accordance with the authors’ protocols. With respect
to the observations regarding the inaccuracy of 16S rRNA
sequencing results of non-tuberculous mycobacteria made by
Turenne and others,24 sequencing of the two additional regions
of the M. ulcerans genome served as a quality-assurance
measure.23–26
Sequence analysis. Sequences were analyzed using DNASIS
Max software (MiraiBio, San Francisco, CA) and aligned with
the M. ulcerans wild-type sequence (Agy99) of the respective gene. BLASTn analysis was performed on entries of
GenBank. Quality assurance of 16S rRNA and ITS results
was performed within ribosomal differentiation of microorganisms (RIDOM).24
Definite sequences were defined as wild type (WT; 100%
nucleotide concordance with M. ulcerans, Agy99) or mutation (MUT; < 3% nucleotide deviation from the WT for
the respective gene and positive species identification for M.
ulcerans). No result (NR) subsumes non-analyzable sequences
[i.e., negative (non-amplifiable) and contaminated (mixed)
sequences as well as sequences deviating > 3% from the WT].
For each patient, the sequencing results of different specimens
were aligned, and the consensus result (WT, MUT, or NR) is
shown in Table 1.
Comparison of whole-genome extracts with culture
extracts. The efficiency of sequencing was defined as the
number of analyzable sequences divided by the number of
extracts subjected to sequencing. The overall efficiencies of
sequencing of rpoB and rpsL genes from all whole-genome
extracts analyzed in this study were compared with those from
all available culture extracts of clinical specimens from all
patients and types of lesions (Table 2).
Comparison of whole-genome extracts with corresponding
culture extracts. From 45 patients (ulcerative and nonulcerative lesions), whole-genome extracts and culture
material derived from corresponding swab and/or tissue
samples obtained from the same patients were available for
comparison. The efficiencies of sequencing of rpoB and rpsL
genes from whole-genome extracts were directly compared
with those of the corresponding culture extracts (Table 3).
Statistical analysis. For all statistical analyses, approximate
tests (χ2 tests) and exact tests (Fisher’s exact tests) were conducted using Stata software (version 9.0; Stata Corp., College
Station, TX). The results of statistical analyses were presented
by means of P values, whereby significant differences were
defined as P values below 0.05. P values did not serve only for
hypothesis testing but as base for discussion. The study was
cross-sectional, and no specific selection or randomization of
study participants was performed.
RESULTS
Laboratory confirmation. From all 162 patients (100%),
the IS2404 DRB-PCR result was positive. Of those, positive
culture results (confirmed by standard IS2404 PCR) were
obtained from 87 patients (53; 7%).
RpoB sequencing results per patient. Definite sequencing
results of the rpoB gene (obtained from culture isolates and/or
whole-genome extracts from swab and/or tissue samples) were
retrieved from 109 of 162 laboratory-confirmed cases (67.3%).
The rpoB WT sequence of M. ulcerans was detected in 108
patients (99.1%; Table 1). The isolate of one patient (0.9%;
treatment group S+NK) showed a mutation at codon Ser522
1062
BEISSNER AND OTHERS
Table 2
Comparison of rpoB and rpsL gene-sequencing results of whole-genome extracts and culture extracts
Culture extracts*
Sequenced genes
rpoB§
Total analyzed
Definite sequences¶
Non-analyzable||
Negative**
Mixed††
rpsL‡‡
Total analyzed
Definite sequences¶
Non-analyzable||
Negative**
Mixed††
Whole-genome extracts†
Swab extracts
Tissue extracts
Total
Swab extracts
Tissue extracts
Total
39
35 (89.7%)
4 (10.3%)
3 (75%)
1 (25%)
57
53 (93.0%)
4 (7.0%)
3 (75%)
1 (25%)
96
88 (91.7%)
8 (8.3%)
6 (75%)
2 (25%)
64
25 (39.1%)
39 (60.9%)
23 (59%)
16 (41%)
92
30 (32.6%)
62 (67.4%)
41 (66.1%)
21 (33.9%)
156
55 (35.3%)
101 (64.7%)
64 (63.4%)
37 (36.6%)
26
23 (88.5%)
3 (11.5%)
2 (66.7%)
1 (33.3%)
41
33 (80.5%)
8 (19.5%)
7 (87.5%)
1 (12.5%)
67
56 (83.6%)
11 (16.4%)
9 (81.8%)
2 (18.2%)
50
16 (32.0%)
34 (68.0%)
21 (61.8%)
13 (38.2%)
69
27 (39.1%)
42 (60.9%)
31 (73.8%)
11 (26.2%)
119
43 (36.1%)
76 (63.9%)
52 (68.4%)
24 (31.6%)
P value‡
< 0.01
< 0.01
Table 2 shows rpoB- and rpsL-sequencing results from whole-genome extracts and culture extracts of 162 IS2404 PCR-confirmed BUD patients.
* DNA was extracted from mycobacterial cultures that were inoculated from swab or tissue specimens.
† DNA was extracted from tissue or swab specimens as whole-genome extracts.
‡ P value is the comparison of efficiencies of definite sequences from the total of whole-genome extracts and culture extracts.
§ rpoB is a 324-bp region of the mycobacterial rpoB gene comprising the rifampicin resistance-determining region (RRDR).
¶ Number of extracts with definite sequences.
|| Number of extracts with non-analyzable sequences (the result is a mixed or non-amplifiable sequence in PCR).
** Number of extracts with non-amplifiable sequences (negative).
†† Mixed sequence is the number of extracts that could not be analyzed, because amplified sequences were contaminated.
‡‡ RpsL is the complete sequence of the gene encoding the ribosomal protein S12 (375 bp).
(M. tuberculosis numbering) within the RRDR, leading to
a transversion of thymine to guanine (TCC to GCC) and
resulting in an amino acid change from serine to alanine.
Species identification allowed the distinct allocation of the
strain to M. ulcerans by 100% nucleotide concordance with
the 16S rRNA, rpsL, hsp65 genes and the ITS of M. ulcerans
strain Agy99.
For 53 patients (32.7%), no result could be obtained (NR).
Among these, five strains showed highly deviated rpoB
sequences (> 3% aberrance) from the M. ulcerans WT. Species
identification, however, did not allow the allocation to a disTable 3
Comparison of corresponding whole-genome extracts and culture
extracts
Corresponding specimens*
Sequenced genes
rpoB¶
Total analyzed
Definite sequences||
Non-analyzable**
Negative§
Mixed††
rpsL‡‡
Total analyzed
Definite sequences||
Non-analyzable**
Negative§
Mixed††
Culture extracts†
Whole-genome extracts‡
45
44 (97.8%)
1 (2.2%)
0
1 (100%)
45
19 (42.2%)
26 (57.8%)
12 (46.2%)
14 (53.8%)
45
41 (91.1%)
4 (8.9%)
4 (100%)
0
45
16 (35.6%)
29 (64.4%)
19 (65.5%)
10 (34.5%)
P value§
< 0.01
< 0.01
Table 3 shows rpoB- and rpsL-sequencing results of corresponding whole-genome and
culture extracts.
* From 45 patients, culture extracts (inoculated from swab or tissue specimens) were analyzed, and results are compared with the corresponding whole-genome extract.
† DNA was extracted from cultured strains that were inoculated from swab or tissue specimens (for ulcerative lesions) or solely from tissue specimens of non-ulcerative lesions.
‡ DNA was extracted from tissue or swab specimens as whole-genome extracts from ulcerative lesions and solely from tissue specimens of non-ulcerative lesions. Per patient, either a
swab or a tissue specimen was analyzed corresponding to the specimen of which a mycobacterial culture was inoculated and a positive confirmatory IS2404 PCR result was obtained.
¶ rpoB is a 324-bp sequence of the mycobacterial rpoB gene comprising the rifampicin
resistance-determining region (RRDR).
|| Number of extracts with definite sequences.
** Number of extracts with non-analyzable sequences (the result is a mixed or non-amplifiable sequence in PCR).
§ Number of extracts with non-amplifiable sequences (negative).
†† Mixed sequence is the number of extracts that could not be analyzed, because amplified
sequences were contaminated.
‡‡ RpsL is the sequence of the gene for ribosomal protein S12 (complete sequence = 375 bp).
tinct mycobacterial species; therefore, a contamination with
closely related species could not be excluded for these cases.
RpsL sequencing results per patient. Definite sequencing
results of the rpsL gene (obtained from culture isolates and/or
whole-genome extracts from swab and/or tissue samples) were
retrieved for 74 of 125 laboratory-confirmed patients (59.2%).
All of these showed the M. ulcerans WT rpsL sequence. For 51
patients (40.8%), no results could be obtained (NR; Table 1).
Comparison of whole-genome extracts with culture
extracts. Among all clinical specimens analyzed in this study,
the overall efficiency of rpoB sequencing of culture extracts
(91.7%) was significantly higher (P < 0.01) than the efficiency
of sequencing of whole-genome extracts (35.3%). Likewise,
the overall efficiency of rpsL sequencing of culture extracts
(83.6%) was significantly higher (P < 0.01) than the efficiency
of sequencing of whole-genome extracts (36.1%).
Among the whole-genome extracts, 64.7% of the rpoB
sequences (63.4% negative and 36.6% mixed) and 63.9% of
the rpsL sequences (68.4% negative and 31.6% mixed) were
non-analyzable. Among the culture extracts, 8.3% of the rpoB
sequences (75% negative and 25% mixed) and 16.4% of the
rpsL sequences (81.8% negative and 18.2% mixed) were nonanalyzable (Table 2).
Comparison of whole-genome extracts with corresponding
culture extracts. Among clinical samples from patients with
corresponding culture extracts and whole-genome extracts,
the efficiency of rpoB sequencing of culture extracts (97.8%)
was significantly higher (P < 0.01) than that of whole-genome
extracts (44.2%). Likewise, the efficiency of rpsL sequencing from culture extracts (91.1%) was significantly higher
(P < 0.01) than the efficiency of sequencing of whole-genome
extracts (35.6%; Table 3).
Follow-up patients. Among follow-up samples of five
patients who had received full-term antibiotic treatment, WT
rpoB and rpsL sequences were detected in isolates from three
patients, whereas sequences from two patients’ isolates were
not amplifiable; thus, no results were retrieved (NR). For
two patients who had received 21 days of antimycobacterial
treatment, rpoB and rpsL WT sequences were detected for
GENOTYPIC DRUG RESISTANCE TESTING IN M. ULCERANS
one patient and could not be amplified from specimens of the
second patient (NR).
DISCUSSION
Conventional in vitro resistance testing according to the
proportion method constitutes the most widespread technique
within the WHO global surveillance system of antimycobacterial drug resistance of tuberculosis.6 Because of the inability
to cultivate M. leprae, sequence-based detection of drug resistance has successfully been applied for leprosy.10 According to
WHO recommendations, M. leprae isolates with an amino acid
change in a drug resistance-determining region that have been
confirmed by mouse footpad testing to confer phenotypic drug
resistance are scored as resistant.11 Sequence-based resistance
testing was also proven to be a rapid and reliable alternative to
conventional resistance testing of M. tuberculosis.7,8
M. ulcerans strains expressing phenotypic and genotypic
resistance were generated under RMP monotherapy in a
mouse model, but systematic drug resistance surveillance in
clinical M. ulcerans strains has not yet been conducted.16
To obtain baseline data on resistance to RMP and SM in
Ghana, we screened clinical M. ulcerans isolates obtained
from BUD patients treated by surgery and/or antimycobacterial drugs. At the time of the study, conventional susceptibility
testing for M. ulcerans was not established in Ghana; therefore, we applied a sequence-based approach for the detection
of mutations associated with drug resistance.
Our findings showed no mutations among patients without previous antimycobacterial treatment. One strain isolated
from a patient treated by surgery and concomitant antibiotic
therapy as early as 2004 (information on drug combination,
dosage, and duration of treatment could not be retrieved from
the files) expressed a mutation at codon Ser522 of the rpoB
gene. The respective mutation was also described by Marsollier
et al.16 after RMP monotherapy of experimentally infected
mice, and phenotypic resistance was confirmed.16 These findings suggest that antimycobacterial treatment, especially
if administered as monotherapy or in an irregular, nonstandardized fashion, may also lead to rpoB mutations of
human M. ulcerans isolates. To establish phenotypic correlates of the mutation detected in the respective strain, conventional susceptibility testing was attempted. However, we did
not succeed in obtaining subcultures from the original isolate.
Mutations of the rpsL gene were not detected. This may be
related to the fact that streptomycin is applied intramuscularly
and has presumably not been administered in monotherapy.
According to current WHO recommendations, all new BUD
cases are subjected to drug treatment. Patients who develop a
new BUD lesion after complete healing of the initial lesion
(recurrences) and BUD patients who missed a total of 14 days
since the start of treatment (defaulters) may receive a second
course of antimycobacterial therapy with regard of the SM lifetime dose (90 g in adults).27 Since the introduction of antimycobacterial treatment in 2006, more than 3,000 BUD cases have
been reported in Ghana, and presumably, the majority of these
cases have been subjected to drug treatment (Asiedu K, personal communication). Whereas human-to-human transmission plays a crucial role for the spread of resistant MTBC and
M. leprae strains, according to current knowledge, M. ulcerans
is acquired from the environment.1,28–30 With only a few
reported cases of infections contracted from humans, the risk
1063
of transmitting resistant strains among populations afflicted
with BUD may be considered minimal.31,32
The rate of drug resistance detected in our study among
clinical M. ulcerans isolates obtained between 2004 and 2007
was low (0.9%). Nevertheless, the emergence of drug-resistant
strains is possible and will, in the first place, affect the treatment outcome of individual patients under antimycobacterial treatment.16,33,34 Therefore, monitoring of drug resistance
will facilitate individual clinical management decisions, especially in recurrences, defaulters, and patients with non-healing
lesions.
With respect to the long generation time of M. ulcerans and
the limited sensitivity of the method, especially in pre-treated
patients, cultures alone are not ideal for genotypic drug resistance testing.5 Especially for clinical management decisions,
whole-genome extracts constitute a better diagnostic target to
obtain rapid results. In our study, analysis of cultured isolates
yielded definite sequencing results for rpoB and rpsL genes in
> 80%, whereas the number of definite results obtained from
whole-genome extracts was significantly lower (< 40% for rpoB
and rpsL genes). The percentage of non-analyzable sequences
among whole-genome extracts was > 60%. Among these, the
respective sequences of 63.4% of the rpoB and 68.4% of the
rpsL genes were non-amplifiable. In general, the presence of
only a low amount of mycobacterial DNA in clinical samples
often hampers diagnostic procedures and may also constitute
a source of error in the present study.35 Amplification of mixed
sequences from related species existing as commensals on the
human skin represents another challenge in sequencing of
whole-genome extracts.
According to the results of this study, the authors consider
it essential to apply refined techniques in further studies. The
design of more specific primers can improve the efficiency of
sequencing of whole-genome extracts. Optimization of extraction procedures (e.g., mechanical homogenization by zirconium beads followed by enzymatic lysis) can augment the
yield of M. ulcerans DNA recovered from swab and tissue
samples.36 Immunomagnetic separation, developed and successfully applied in environmental studies by Marsollier and
others,37 may be a promising tool to concentrate and purify
M. ulcerans from clinical samples; however, this technique is
currently restricted to BUD reference laboratories or collaborative research programs.
From 12% of the study subjects, documentation of previous
antimycobacterial treatment could not be retrieved from the
clinical records. These partially incomplete sets of data, therefore, constitute a weakness of this study. With respect to correct interpretation of results, further studies on drug resistance
in M. ulcerans should aim at obtaining complete and detailed
patient-related information. WHO provides a form (BU01)
for the recording of clinical, epidemiological, and treatment
data, which, in general, is available in all endemic countries.
A consequent use of the BU01 form will facilitate the collection of relevant information.1
Received May 9, 2010. Accepted for publication July 30, 2010.
Acknowledgments: Primer sequences (rpsL-F and rpsL-R) were
kindly provided by F. Portaels and P. Stragier (Institute for Tropical
Medicine, Antwerp, Belgium). The authors thank David Schenavsky
for proofreading of the manuscript. The article contains parts of the
doctoral dissertation of Marcus Beissner. There is no conflict of interest
among authors.
1064
BEISSNER AND OTHERS
Financial support: This project was supported by the European
Commission (Project INCO-CT-2005-015476-BURULICO).
Authors’ addresses: Marcus Beissner, Joerg Nitschke, Karl-Heinz
Herbinger, Vera Siegmund, Erna Fleischmann, Thomas Loscher,
and Gisela Bretzel, Department of Infectious Diseases and Tropical
Medicine (DITM), University Hospital, Ludwig-Maximilians University
of Munich, Munich, Germany, E-mails: marcus.beissner@lrz.unimuenchen.de, j.a.nitschke@web.de, herbinger@lrz.uni-muenchen.de,
v.siegmund@eurice.de, erna.fleischmann@lrz.uni-muenchen.de, loe
scher@lrz.uni-muenchen.de, and bretzel@lrz.uni-muenchen.de. NanaYaa Awua-Boateng and Ohene Adjei, Kumasi Centre for Collaborative
Research in Tropical Medicine (KCCR), Kwame Nkrumah University
of Science and Technology, Kumasi, Ghana, E-mails: awua.boateng@
kccr.de and oadjei@africaonline.com.gh. William Thompson, Agogo
Presbyterian Hospital, Agogo, Ghana, E-mail: wnat@agogohospital
.org.Willemien A. Nienhuis and Tjip S. van der Werf, University Medical
Centre Groningen (UMCG), University of Groningen, Groningen,
The Netherlands, E-mails: wiannix@hotmail.com and t.s.van.der
.werf@int.umcg.nl. Erasmus Klutse, Dunkwa Governmental Hospital,
Dunkwa-on-Offin, Dunkwa, Ghana, E-mail: eyklutse@yahoo.com.
Pius Agbenorku, Reconstructive Plastic Surgery and Burns Unit,
Department of Surgery, Komfo Anokye Teaching Hospital, Kwame
Nkrumah University of Science and Technology, Kumasi, Ghana,
E-mail: pimagben@yahoo.com. Bernhard Fleischer, Bernhard Nocht
Institute for Tropical Medicine (BNITM), Hamburg, Germany, E-mail:
fleischer@bni-hamburg.de.
Reprints requests: Gisela Bretzel, Department of Infectious Diseases
and Tropical Medicine, University Hospital, Ludwig-Maximilians
University of Munich, Leopoldstrasse 5, 80802 Munich, Germany,
E-mail: bretzel@lrz.uni-muenchen.de.
REFERENCES
1. World Health Organization, 2008. Buruli ulcer: progress report,
2004–2008. Wkly Epidemiol Rec 17: 145–154.
2. World Health Organization, 2004. Provisional Guidance on the
Role of Specific Antibiotics in the Management of Mycobacterium
ulcerans Disease (Buruli Ulcer). Geneva, Switzerland: World
Health Organization.
3. Siegmund V, Adjei O, Nitschke J, Thompson W, Klutse E, Herbinger
KH, Thompson R, van Vloten F, Racz P, Fleischer B, Loescher T,
Bretzel G, 2007. Dry reagent-based polymerase chain reaction
compared with other laboratory methods available for the diagnosis of Buruli ulcer disease. Clin Infect Dis 45: 68–75.
4. Schunk M, Thompson W, Klutse E, Nitschke J, Opare-Asamoah K,
Thompson R, Fleischmann E, Siegmund V, Herbinger KH,
Adjei O, Fleischer B, Loscher T, Bretzel G, 2009. Outcome of
patients with Buruli ulcer after surgical treatment with or without antimycobacterial treatment in Ghana. Am J Trop Med
Hyg 81: 75–81.
5. Herbinger KH, Adjei O, Awua-Boateng NY, Nienhuis WA, Kunaa L,
Siegmund V, Nitschke J, Thompson W, Klutse E, Agbenorku P,
Schipf A, Reu S, Racz P, Fleischer B, Beissner M, Fleischmann E,
Helfrich K, van der Werf TS, Loscher T, Bretzel G, 2009.
Comparative study of the sensitivity of different diagnostic methods for the laboratory diagnosis of Buruli ulcer disease. Clin Infect
Dis 48: 1055–1064.
6. World Health Organization, 2008. Anti-Tuberculosis Drug
Resistance in the World. Report No. 4. Geneva, Switzerland:
World Health Organization.
7. Van Rie A, Warren R, Mshanga I, Jordaan AM, van der Spuy GD,
Richardson M, Simpson J, Gie RP, Enarson DA, Beyers N, van
Helden PD, Victor TC, 2001. Analysis for a limited number of
gene codons can predict drug resistance of Mycobacterium
tuberculosis in a high-incidence community. J Clin Microbiol
39: 636–641.
8. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B,
Takiff HE, Cole ST, 1997. Genotypic assessment of isoniazid
and rifampin resistance in Mycobacterium tuberculosis: a blind
study at reference laboratory level. J Clin Microbiol 35:
719–723.
9. World Health Organization, 2007. Rifampicin Resistance in Leprosy.
Report of an Informal Consultation. Geneva, Switzerland: World
Health Organization.
10. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED,
Gelber R, Saunderson P, Balagon V, Pannikar V, 2007. The frequency of drug resistance mutations in Mycobacterium leprae
isolates in untreated and relapsed leprosy patients from
Myanmar, Indonesia and the Philippines. Lepr Rev 78: 343–352.
11. World Health Organization, 2009. Guidelines for Global
Surveillance of Drug Resistance in Leprosy. Geneva, Switzerland:
World Health Organization.
12. Morlock GP, Plikaytis BB, Crawford JT, 2000. Characterization of
spontaneous in vitro-selected, rifampin-resistant mutants of
Mycobacterium tuberculosis strain H37Rv. Antimicrob Agents
Chemother 44: 3298–3301.
13. Sapkota BR, Ranjit C, Neupane KD, Macdonald M, 2008.
Development and evaluation of a novel multiple-primer PCR
amplification refractory mutation system for the rapid detection of mutations conferring rifampicin resistance in codon 425
of the rpoB gene of Mycobacterium leprae. J Med Microbiol 57:
179–184.
14. Das R, Gupta P, Singh P, Chauhan DS, Katoch K, Katoch VM,
2009. Association of mutations in rpsL gene with high degree of
streptomycin resistance in clinical isolates of Mycobacterium
tuberculosis in India. Indian J Med Res 129: 108–110.
15. Mieskes KT, Rusch-Gerdes S, Truffot-Pernot C, Feldmann K,
Tortoli E, Casal M, Loscher T, Rinder H, 2000. Rapid, simple,
and culture-independent detection of rpsL codon 43 mutations
that are highly predictive of streptomycin resistance in
Mycobacterium tuberculosis. Am J Trop Med Hyg 63: 56–60.
16. Marsollier L, Honore N, Legras P, Manceau AL, Kouakou H,
Carbonnelle B, Cole ST, 2003. Isolation of three Mycobacterium
ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother 47: 1228–1232.
17. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM,
Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten
JP, Adjei O, Bretzel G, van der Werf TS, 2010. Antimicrobial
treatment for early, limited Mycobacterium ulcerans infection: a
randomized controlled trial. Lancet 375: 664–672.
18. Stinear T, Ross BC, Davies JK, Marino L, Robins-Browne RM,
Oppedisano F, Sievers A, Johnson PD, 1999. Identification and
characterization of IS2404 and IS2606: two distinct repeated
sequences for detection of Mycobacterium ulcerans by PCR.
J Clin Microbiol 37: 1018–1023.
19. Siegmund V, Adjei O, Racz P, Berberich C, Klutse E, van Vloten F,
Kruppa T, Fleischer B, Bretzel G, 2005. Dry reagent-based PCR
as a novel tool for laboratory confirmation of clinically diagnosed
Mycobacterium ulcerans-associated disease in areas in the tropics where M. ulcerans is endemic. J Clin Microbiol 43: 271–276.
20. Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson R,
Fleischmann E, Fleischer B, Adjei O, 2006. External quality
assurance for the laboratory diagnosis of Buruli ulcer disease in
Ghana. Trop Med Int Health 11: 1688–1693.
21. Bretzel G, Siegmund V, Nitschke J, Herbinger KH, Thompson W,
Klutse E, Crofts K, Massavon W, Etuaful S, Thompson R,
Asamoah-Opare K, Racz P, Vloten F, van Berberich C, Kruppa
T, Ampadu E, Fleischer B, Adjei O, 2007. A stepwise approach
to the laboratory diagnosis of Buruli ulcer disease. Trop Med
Int Health 12: 89–96.
22. Kim BJ, Lee SH, Lyu MA, Kim SJ, Bai GH, Chae GT, Kim EC,
Cha CY, Kook YH, 1999. Identification of mycobacterial species by comparative sequence analysis of the RNA polymerase
gene (rpoB). J Clin Microbiol 37: 1714–1720.
23. Talaat AM, Reimschuessel R, Trucksis M, 1997. Identification of
mycobacteria infecting fish to the species level using polymerase chain reaction and restriction enzyme analysis. Vet
Microbiol 58: 229–237.
24. Turenne CY, Tschetter L, Wolfe J, Kabani A, 2001. Necessity of
quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous Mycobacterium species. J Clin Microbiol
39: 3637–3648.
25. Kim H, Kim SH, Shim TS, Kim MN, Bai GH, Park YG, Lee SH,
Cha CY, Kook YH, Kim BJ, 2005. PCR restriction fragment
length polymorphism analysis (PRA)-algorithm targeting 644
bp Heat Shock Protein 65 (hsp65) gene for differentiation of
Mycobacterium spp. J Microbiol Methods 62: 199–209.
26. Roth A, Reischl U, Streubel A, Naumann L, Kroppenstedt RM,
Habicht M, Fischer M, Mauch H, 2000. Novel diagnostic algorithm for identification of mycobacteria using genus-specific
GENOTYPIC DRUG RESISTANCE TESTING IN M. ULCERANS
27.
28.
29.
30.
31.
amplification of the 16S-23S rRNA gene spacer and restriction
endonucleases. J Clin Microbiol 38: 1094–1104.
World Health Organization, 2007. Summary Report of the WHO
Annual Meeting on Buruli Ulcer. Geneva, Switzerland: World
Health Organization.
Eddyani M, Ofori-Adjei D, Teugels G, De Weirdt D, Boakye D,
Meyers WM, Portaels F, 2004. Potential role for fish in transmission of Mycobacterium ulcerans disease (Buruli ulcer): an environmental study. Appl Environ Microbiol 70: 5679–5681.
Johnson PD, Azuolas J, Lavender CJ, Wishart E, Stinear TP,
Hayman JA, Brown L, Jenkin GA, Fyfe JA, 2007. Mycobacterium
ulcerans in mosquitoes captured during outbreak of Buruli
ulcer, southeastern Australia. Emerg Infect Dis 13: 1653–1660.
van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O,
Fleischer B, Wansbrough-Jones MH, Johnson PD, Portaels F,
van der Graaf WT, Asiedu K, 2005. Mycobacterium ulcerans
disease. Bull World Health Organ 83: 785–791.
Debacker M, Zinsou C, Aguiar J, Meyers WM, Portaels F, 2003.
First case of Mycobacterium ulcerans disease (Buruli ulcer) following a human bite. Clin Infect Dis 36: e67–e68.
1065
32. Maranes Antonanzas I, Lopez Gallardo Y, Garcia Pardo A, Abella
Vazquez ML, 2006. Transmission of Buruli ulcer from person to
person. Rev Clin Esp 206: 256–257.
33. Asiedu K, Wansbrough-Jones M, 2007. Mycobacterium ulcerans
infection (Buruli or Bairnsdale ulcer): challenges in developing
management strategies. Med J Aust 186: 55–56.
34. Eddyani M, Debacker M, Martin A, Aguiar J, Johnson CR,
Uwizeye C, Fissette K, Portaels F, 2008. Primary culture of
Mycobacterium ulcerans from human tissue specimens after
storage in semisolid transport medium. J Clin Microbiol 46:
69–72.
35. Pierre-Audigier C, 1994. Recent biological techniques for the diagnosis of mycobacterial infections. Presse Med 23: 665–670.
36. Hosek J, Svastova P, Moravkova M, Pavlik I, Bartos M, 2006.
Methods of mycobacterial DNA isolation from different biological material: a review. Vet Med (Praha) 51: 180–192.
37. Marsollier L, Robert R, Aubry J, Saint Andre JP, Kouakou H,
Legras P, Manceau AL, Mahaza C, Carbonnelle B, 2002. Aquatic
insects as a vector for Mycobacterium ulcerans. Appl Environ
Microbiol 68: 4623–4628.